The Times Australia
News From Asia

.

G-NiiB Oral Microbiome Immunity Formula SIM01 Alleviates Post-COVID-19 Conditions

Clinical Study Published in the Prestigious International Medical Journal The Lancet Infectious Diseases

HONG KONG SAR - Media OutReach Newswire - 8 December 2023 - Hong Kong's leading biomedical and microbiome technology company, G-NiiB GenieBiome, is pleased to announce that a ground-breaking large-scale randomised, double-blind, placebo-controlled clinical trial ("the Trial") conducted on the efficacy of SIM01, an oral microbiome immunity formula developed by a top-notch medical school in Hong Kong, involving 463 patients who had contracted COVID-19, has strongly proved that the consumption of SIM01, an oral microencapsulated live bacteria formula, could significantly improve the gut microbiota after six months and lead to remarkable alleviation of post-COVID-19 sequelae ("long COVID"), encompassing a range of symptoms affecting different systems and organs.

The findings of the Trial were published yesterday in The Lancet Infectious Diseases, the most authoritative international medical journal in infectious diseases.

G-NiiB GenieBiome’s flagship product, G-NiiB Immunity+, contains the oral microbiome immunity formula SIM01.
G-NiiB GenieBiome’s flagship product, G-NiiB Immunity+, contains the oral microbiome immunity formula SIM01.

The Trial has robustly demonstrated the exceptional efficacy of SIM01 in alleviating post-COVID-19 conditions, sending a significant breakthrough and a sliver of hope for the 65 million individuals worldwide who have been profoundly impacted by the long COVID. It is widely acknowledged that post-COVID-19 symptoms exhibit substantial interindividual variability, complexity, and long-haul span, posing a dual challenge to the patient's physiological and psychological well-being. Given the current lack of targeted and effective therapies, it has emerged as one of the most formidable health challenges in the aftermath of the COVID-19 pandemic. In its August 2021 publication, The Lancet mentioned that long COVID is the primary challenge of modern medicine.

The oral microencapsulated live bacteria formula SIM01, published in The Lancet Infectious Diseases this time, is the flagship product of G-NiiB GenieBiome. Multiple clinical studies have confirmed its effectiveness. This very study, known as the RECOVERY study, is the first global clinical research to testify that SIM01 can improve gut microbiota and effectively alleviate post-COVID-19 symptoms, including fatigue, memory loss, difficulty in concentration, gastrointestinal upset and general unwellness. The study results further highlight the interconnectedness of the "Microbiome-Gut-Brain Axis," illustrating how probiotic metabolites absorbed through the gut can contribute to improving brain function. This also underscores the potential of restoring healthy gut microbiota as a novel intervention and strategy for addressing post-COVID-19 neurological symptoms. The publication of these research findings in The Lancet Infectious Diseases signifies authoritative recognition of their scientific and pioneering property, as well as a strong affirmation of SIM01's possibility to improve post-COVID-19 symptoms and enhance overall immune performance in patients.

Ms. Rachel Fan, CEO of G-NiiB GenieBiome, stated, "The publication of the Trial on G-NiiB's microbiome immunity formula, SIM01, in the medical journal The Lancet Infectious Diseases, is undoubtedly a scientific feat and a significant milestone for G-NiiB GenieBiome. It represents a great recognition of the leadership, judgment, and expertise of our founder and Chief Scientific Advisor, showcasing our leading position and innovative capabilities in microbiome research. It also serves as a strong testimony of our professional competence and product quality, demonstrating that our core technology has received authoritative approbation from the international medical community. This is considerable progress and an outstanding achievement for a pioneering company to keep a foothold in the microbiome arena. We are immensely proud."

Besides, "The practical significance of this study lies in proving the scientific efficacy and multiple feasibilities of SIM01, inaugurating new avenues for microbiome research and human health exploration. From a societal perspective, G-NiiB's microbiome immunity formula, SIM01, presents the potential to offer a fresh choice for individuals suffering from long COVID while making seminal contributions to the fight against COVID-19 and other diseases. G-NiiB GenieBiome is committed to continuing its investment in innovative research and cutting-edge development, steadfastly striving to improve human health and tackle various disease challenges."

Ms. Rachel Fan, CEO of G-NiiB GenieBiome, background is the clinical trial published in The Lancet Infectious Diseases.
Ms. Rachel Fan, CEO of G-NiiB GenieBiome, background is the clinical trial published in The Lancet Infectious Diseases.

Utilising advanced metagenomic sequencing data, patented artificial intelligence, and microencapsulation technology, G-NiiB GenieBiome has introduced three patented oral microbiota formulations. They are SIM01, a microbiome precision immunity formula designed to enhance the immune system; SMT04, a microbiome precision gut protective formula to preserve intestinal health; and SIM03, a microbiome precision children immunity formula to develop diverse rainbow immunity. Clinical data from a renowned medical school in Hong Kong have supported these formulations. The team is currently researching to develop innovative formulations to treat and alleviate complex conditions such as fatty liver and adult eczema, aiming to meet the evolving needs of the health supplement market.

Ms. Rachel Fan further added, "Our core team members excel in their respective spheres. Our collective goal is to blaze innovative transformation in the field of human health through microbiome research. By leveraging the leap we made in microbiota research, the team strives to significantly improve disease prevention, diagnosis, and treatment, sequentially accelerating the transition into a new era of microbiota-centric medicine."
Hashtag: #G-NiiBGenieBiome #SIM01 #LancetInfectiousDiseases #COVD-19 #RECOVERY #synbiotic #PACS






The issuer is solely responsible for the content of this announcement.

G-NiiB GenieBiome

G-NiiB GenieBiome is a biotechnology company founded by world-renowned clinician-scientists and supported by a multidisciplinary team of experts in microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical trials, IP development and commercialization. For over a decade, our team has pioneered the use of microbiome with evidence-based science to tackle a myriad of diseases, including colorectal cancer, obesity, atopic eczema, autism, and mood disorders, revolutionizing the prevention, diagnosis, and treatment of disease. Our precision portfolio of G-NiiB includes diagnostic and risk prediction tests, next-generation microbiome precision formulas, and precision medicine tailored for the Asian population. Our vision is to be a game changer in human health with microbiome solutions.

Times Magazine

Building a Strong Online Presence with Katoomba Web Design

Katoomba web design is more than just creating a website that looks good—it’s about building an online presence that reflects your brand, engages your audience, and drives results. For local businesses in the Blue Mountains, a well-designed website a...

September Sunset Polo

International Polo Tour To Bridge Historic Sport, Life-Changing Philanthropy, and Breath-Taking Beauty On Saturday, September 6th, history will be made as the International Polo Tour (IPT), a sports leader headquartered here in South Florida...

5 Ways Microsoft Fabric Simplifies Your Data Analytics Workflow

In today's data-driven world, businesses are constantly seeking ways to streamline their data analytics processes. The sheer volume and complexity of data can be overwhelming, often leading to bottlenecks and inefficiencies. Enter the innovative da...

7 Questions to Ask Before You Sign IT Support Companies in Sydney

Choosing an IT partner can feel like buying an insurance policy you hope you never need. The right choice keeps your team productive, your data safe, and your budget predictable. The wrong choice shows up as slow tickets, surprise bills, and risky sh...

Choosing the Right Legal Aid Lawyer in Sutherland Shire: Key Considerations

Legal aid services play an essential role in ensuring access to justice for all. For people in the Sutherland Shire who may not have the financial means to pay for private legal assistance, legal aid ensures that everyone has access to representa...

Watercolor vs. Oil vs. Digital: Which Medium Fits Your Pet's Personality?

When it comes to immortalizing your pet’s unique personality in art, choosing the right medium is essential. Each artistic medium, whether watercolor, oil, or digital, has distinct qualities that can bring out the spirit of your furry friend in dif...

The Times Features

NSW has a new fashion sector strategy – but a sustainable industry needs a federally legislated response

The New South Wales government recently announced the launch of the NSW Fashion Sector Strategy, 2025–28[1]. The strategy, developed in partnership with the Australian Fashion ...

From Garden to Gift: Why Roses Make the Perfect Present

Think back to the last time you gave or received flowers. Chances are, roses were part of the bunch, or maybe they were the whole bunch.   Roses tend to leave an impression. Even ...

Do I have insomnia? 5 reasons why you might not

Even a single night of sleep trouble can feel distressing and lonely. You toss and turn, stare at the ceiling, and wonder how you’ll cope tomorrow. No wonder many people star...

Wedding Photography Trends You Need to Know (Before You Regret Your Album)

Your wedding album should be a timeless keepsake, not something you cringe at years later. Trends may come and go, but choosing the right wedding photography approach ensures your ...

Can you say no to your doctor using an AI scribe?

Doctors’ offices were once private. But increasingly, artificial intelligence (AI) scribes (also known as digital scribes) are listening in. These tools can record and trans...

There’s a new vaccine for pneumococcal disease in Australia. Here’s what to know

The Australian government announced last week there’s a new vaccine[1] for pneumococcal disease on the National Immunisation Program for all children. This vaccine replaces pr...